

DR. METZGER'S SATURDAY EVENING NEWSLETTER

FOR APRIL 15, 2023

PROSTATE FORUM OF ORANGE COUNTY

WWW.PROSTATEFORUM.ORG

UROLOGY TODAY, Feb 23, 2023

“Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels

By: [Jordyn Sava](#)

One of the most important things we do at the Forum is educate patients and others about detection and treatment that have powerful potential to save their lives and / or prevent further damage to their bodies. Better detection leads to important, lifesaving changes in treatment. Here's an example.

Tonight, I sharing a recent Canadian study that demonstrates how well a Prostate Specific Membrane Antigen called “Piflufolastat F 18” or “Pylarify” used with PET / CT scan can locate metastatic prostate cancer in post treatment patients with low PSA levels. I'll put a link to the UROLOGY TODAY article about this study at the end of this newsletter.

Post treatment men, 208 in all had evidence of prostate cancer reoccurrence and / or metastasis in spite of low PSA levels. By low, I mean 0.2 ng /nl to 0.5 ng / nl. Here's what happened when those men were given Pylarify prior to a PET / CT scan.

- 208 men with a median baseline PSA of 0.8 ng/mL (range, 0.2-98.4 ng/mL) were enrolled and given piflufolastat F 18. Findings revealed that the correct localization rate was 84.8%-87.0% (lower bound of 95% CI, 77.8-80.4), and the disease detection rate was 59%-66%.³
- Investigators reviewed data from a subset of 69 patients who had a PSA level below 0.5 ng/mL.¹ In the study, patients received a single dose injection of piflufolastat F 18 prior to PET imaging and completed pre- and post-imaging questionnaires about the intended management of their prostate cancer.
- Nearly 40% of patients changed how they went about future treatment from their original post treatment game plan. Nearly two-thirds of patients had their treatment plan altered, attributed to learnings from the scan itself,
- Nearly 75% (20 of 27 of patients) changed their plan from “observation” to starting new treatment or from salvage therapy to systemic therapy.

Here's the link to the original UROLOGY TODAY article:

https://www.urologytimes.com/view/analysis-underscores-value-of-piflufolastat-f-18-imaging-in-men-with-low-psa-levels?utm_source=sfmc&utm_medium=email&utm_campaign=03202023_UT_TEL-23-URD0434_Telix_illucix_Next%20Gen%20Imaging%20TRC&eKey=Y2ttZXR6Z2VyQG1hYy5jb20=